Dashboard
Manage Tickers

NTLAIntellia Therapeutics, Inc.

Nasdaq intelliatx.com


$ 23.59 $ 0.33 (1.42 %)    

Friday, 03-May-2024 15:59:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 23.6
$ 24.44
$ 0.00 x 0
$ 0.00 x 0
$ 23.43 - $ 24.97
$ 19.37 - $ 47.48
1,294,988
na
2.09B
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-26-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 10-31-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-02-2019 03-31-2019 10-Q
21 02-27-2019 12-31-2018 10-K
22 10-31-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-01-2018 03-31-2018 10-Q
25 03-14-2018 12-31-2017 10-K
26 10-31-2017 09-30-2017 10-Q
27 08-01-2017 06-30-2017 10-Q
28 05-02-2017 03-31-2017 10-Q
29 03-14-2017 12-31-2016 10-K
30 11-01-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 06-03-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

intellia-therapeutics-announced-the-acceptance-of-an-oral-presentation-from-the-phase-1-portion-of-the-ongoing-ntla-2002-phase-12-study-at-the-european-academy-of-allergy-and-clinical-immunology-congress-2024
Intellia Therapeutics Announced The Accept...
04/29/2024 11:31:35

wedbush-reiterates-neutral-on-intellia-therapeutics-maintains-29-price-target
Wedbush Reiterates Neutral on Intellia The...
04/23/2024 17:11:21

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $29 price tar...

Core News & Articles
Intellia Therapeutics On March 19, Notifie...
03/22/2024 13:29:44

-SEC Filing

intellia-therapeutics-announces-first-patient-dosed-in-the-phase-3-magnitude-study-of-ntla-2001-as-a-single-dose-crispr-based-treatment-for-transthyretin-amyloidosis-with-cardiomyopathy
Intellia Therapeutics Announces First Pati...
03/18/2024 11:35:57

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...

cathie-woods-ark-invest-offloads-69m-worth-of-coinbase-robinhood-shares-each-amid-searing-bitcoin-rally--nvidia-stock-also-shed
Cathie Wood's Ark Invest Offloads $6.9M Wo...
02/27/2024 03:45:00

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such a...

goldman-sachs-downgrades-intellia-therapeutics-to-neutral-announces-32-price-target
Goldman Sachs Downgrades Intellia Therapeu...
02/23/2024 18:34:33

Goldman Sachs analyst Salveen Richter downgrades Intellia Therapeutics (NASDAQ:NTLA) from Buy to Neutral and announces $32 p...

canaccord-genuity-maintains-buy-on-intellia-therapeutics-raises-price-target-to-73
Canaccord Genuity Maintains Buy on Intelli...
02/23/2024 14:54:24

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target ...

intellia-therapeutics-cash-cash-equivalents-and-marketable-securities-of-1b-with-cash-runway-into-mid-2026
Intellia Therapeutics' Cash, Cash Equivale...
02/22/2024 12:38:53

intellia-therapeutics-q4-eps-146-misses-145-estimate-sales-192m-may-not-be-comparable-to-1283m-estimate
Intellia Therapeutics Q4 EPS $(1.46) Misse...
02/22/2024 12:36:42

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate ...

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

a-preview-of-intellia-therapeuticss-earnings
A Preview Of Intellia Therapeutics's Earnings
02/21/2024 16:01:27

intellia-therapeutics-recode-therapeutics-enter-strategic-collaboration-to-develop-novel-genomic-medicines-for-treatment-of-cystic-fibrosis-no-financial-terms-disclosed
Intellia Therapeutics, ReCode Therapeutics...
02/15/2024 12:34:22

CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestiv...

wolfe-research-initiates-coverage-on-intellia-therapeutics-with-peer-perform-rating
Wolfe Research Initiates Coverage On Intel...
02/15/2024 11:35:54

Wolfe Research analyst Andy Chen initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Peer Perform rating.

not-shy-of-buying-the-dip-cathie-woods-ark-mops-up-over-11m-worth-of-shares-in-tesla--sells-nvidia-stock
Not Shy Of Buying The Dip, Cathie Wood's A...
02/06/2024 03:45:45

cathie-woods-ark-invest-snatches-up-47m-more-in-tesla-shares-invests-equally-in-this-rocket-company
Cathie Wood's Ark Invest Snatches Up $4.7M...
02/02/2024 04:18:45

intellia-therapeutics-reveals-publication-of-interim-phase-1-data-for-ntla-2002-in-patients-with-hereditary-angioedema-in-the-new-england-journal-of-medicine
Intellia Therapeutics Reveals Publication ...
01/31/2024 22:09:21

The company said data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary ang...

Core News & Articles
Regeneron Pharmaceuticals Expects Q4 2023 ...
01/08/2024 11:41:18

intellia-therapeutics-highlights-its-3-year-strategic-priorities-and-anticipated-2024-key-milestones-ended-2023-in-a-strong-financial-position-with-approximately-1b-in-cash-cash-runway-extended-into-mid-2026
Intellia Therapeutics Highlights Its 3-Yea...
01/04/2024 21:02:22

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enroll...

why-renew-energy-global-shares-are-trading-higher-by-around-14-here-are-other-stocks-moving-in-mondays-mid-day-session
Why ReNew Energy Global Shares Are Trading...
11/20/2023 19:35:58

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy ...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
11/17/2023 17:35:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION